Everything below concerns lyophilised powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
== Neutralization == In the duodenum, gastric acid is neutralized by sodium bicarbonate. This also blocks gastric enzymes that function optimally in the acid range of pH. The secretion of bicarbonate from the pancreas is stimulated by secretin. This polypeptide hormone gets activated and secreted from so-called S cells in the mucosa of the duodenum and jejunum when the pH in the duodenum falls below 4.5 to 5.0. The neutralization is described by the equation:
== Financial history == Millipore Corporation had been publicly traded on the OTC, or NASDAQ, exchange where it had paid a cash dividend to shareholders every year since 1966. In 1987 Millipore Corporation moved from the NASDAQ exchange to the New York Stock Exchange, where it traded under the ticker symbol MIL. Millipore Corporation was on the S&P 500 list of the largest publicly traded companies in the United States until it was acquired by Merck kGaA in 2010. The deal was valued at approximately EUR 5.3 billion (US$7.2 billion). Merck KGaA is not associated with Merck & Co., although the two companies stem from the same parent company.
=== Essendon (2006–2014) === Essendon secured Ryder with its first selection in the 2005 AFL draft, which was the seventh pick in the league. He made his debut in round 1, 2006, against Sydney, playing in the ruck and receiving his first AFL career possession after he caught Swans premiership player Amon Buchanan holding the ball and won a free kick. In a memorable debut, the Bombers thrashed the 2005 premiers by 27 points, in what would be their only win inside the first 16 rounds of the season and the only win Ryder enjoyed that year. Ryder was awarded a NAB Rising Star nomination for his efforts in round 1, 2007. He won the Anzac Medal in 2009 after teammate David Hille was injured in the opening minutes of the game, resulting in Ryder rucking unassisted for the rest of the game. Ryder played his 100th AFL game in round 6, 2011, in a match where Essendon defeated the Gold Coast Suns by 139 points. Ryder's improved form in the second half of the 2013 season after struggling with poor output and low confidence saw him play a big role in Essendon’s push to the finals. He played mainly in the ruck, where his tap-work was crucial, and also played forward and in defence. Ryder remained a vital part of the Essendon outfit, firstly as a ruckman and then as an option as he pushed forward with his pace and high-marking ability. Ryder had a solid start to 2014, including a two-goal performance in round 9 against Sydney.
=== Frostbite === Frostbite is a cold-related injury occurring when an area (typically a limb or other extremity) is exposed to extreme low temperatures, causing the freezing of the skin or other tissues. Its pathophysiology involves the formation of ice crystals upon freezing and blood clots upon thawing, leading to cell damage and cell death. Treatment of severe frostbite may require surgical amputation of the affected tissue or limb; if there is deep injury autoamputation may occur.
Iced coffee is coffee served cold. It may be prepared either by brewing coffee normally (i.e. carafe, French press, etc.) and then serving it over ice or with cold milk, or by brewing the coffee cold. In hot brewing, sweeteners and flavoring may be added before cooling, as they dissolve faster. Iced coffee can also be sweetened with pre-dissolved sugar in water. Iced coffee is regularly available in most coffee shops. Iced coffee is generally brewed at a higher strength than normal coffee, to compensate for dilution by melting ice. Iced coffee is made by brewing hot coffee, and pouring it over ice; cold brew coffee is made without heat by steeping coffee grounds into lukewarm water. In Australia, packaged iced coffee with milk and sweetener is widely distributed.
Sources: en.wikipedia.org
. In contrast, for traditional semiconductors, the primary point of interest is generally Γ, where momentum is zero. If the in-plane direction is confined rather than infinite, its electronic structure changes. These confined structures are referred to as graphene nanoribbons. If the nanoribbon has a "zig-zag" edge, the bandgap remains zero. If it has an "armchair" edge, the bandgap is non-zero. Graphene's honeycomb structure can be viewed as two interleaving triangular lattices. This perspective has been used to calculate the band structure for a single graphite layer using a tight-binding approximation.
== Inherited thrombocytopenia with normal MPV == ATRUS Syndrome Thrombocytopenia 2 (THC2) Congenital amegakaryocytic thrombocytopenia TAR syndrome Familial platelet disorder with predisposition to AML
A mass-selecting quadrupole and collision quadrupole with time-of-flight device as the second mass selection stage is a hybrid known as a quadrupole time-of-flight mass spectrometer (QTOF MS). Quadrupole-quadrupole-time-of-flight (QqTOF) configurations are also possible and used especially the mass spectrometry of peptides and other large biological polymers. A variant of the quadrupole mass analyzer called the monopole was invented by von Zahn which operates with two electrodes and generates one quarter of the quadrupole field. It has one circular electrode and one V-shaped electrode. The performance is, however, lower than that of a quadrupole mass analyzer. An enhancement to the performance of the quadrupole mass analyzer has been demonstrated to occur when a magnetic field is applied to the instrument. Manifold improvements in resolution and sensitivity have been reported for a magnetic field applied in various orientations to a QMS.
=== Argentina === In 2011, Argentina introduced a catalogue of drugs covered by its national drug traceability scheme, listing more than 3,000 drugs that require the placing of unique serial numbers and tamper-evident features on the secondary packaging. The drugs listed are recorded in real time in a central database managed by the National Administration of Drugs, Foods, Medical Devices of Argentina (ANMAT), Regulation 3683, which uses Global Location Numbers (GLNs) to identify the various actors in the supply chain. The purpose of this program is to actively limit the use of illegal drugs.
It is a fact that the People's Republic of China is the source for the vast majority of synthetic opioids that are flooding the streets of the United States and Western democracies. It is a fact that these synthetic opioids are responsible for the overwhelming increase in overdose deaths in the United States. It is a fact that if the People's Republic of China wanted to shut down the synthetic opioids industry, they could do so in a day.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.